Petr Knesl

Drugging an undruggable pocket on KRAS

Dirk Kessler, Michael Gmachl, Andreas Mantoulidis et al. · Proceedings of the National Academy of Sciences · 2019 · 434 citations · Full text

Medicine, Molecular Biology, Oncology +15

Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor

Laetitia J. Martin, Manfred Koegl, Gerd Bader et al. · Journal of Medicinal Chemistry · 2016 · 224 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +13

Improved Synthesis of Substituted 6,7-Dihydroxy-4-quinazolineamines: Tandutinib, Erlotinib and Gefitinib

Petr Knesl, Dirk Röseling, Ulrich Jordis · Molecules · 2006 · 61 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +6

Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling

Birgit Wilding, Dirk Scharn, Dietrich Böse et al. · Nature Cancer · 2022 · 53 citations

Medicine, Medicinal Chemistry, Oncology +15